Your English writing platform
Discover LudwigExact(1)
Perhaps we have to be more careful to interpret data of large trials and should unmask typical "large trial diseases".
Similar(59)
In the first trial, disease severity in AMF pre-colonized potato plants was markedly decreased and the onset of late blight symptoms was delayed by 10 days.
Finally, the phenomenon of a "large trial disease" is discussed, exemplary in a trial which investigated the maintenance of the "right" mean arterial pressure in sepsis patients.
In the present trial, disease severity in the population included was greater than anticipated and the death rate was also higher than expected.
In the APEX trial, disease progression led to early discontinuation in 98 patients who received bortezomib (29%) and in 174 (52%) who received dexamethasone (P<0.001) (Richardson et al. 2005a).
In a recent phase IIb trial, disease incidence of DENV3 and DENV4 serotypes was reduced by 80 90% upon vaccination with the tetravalent CYD vaccine.
It is generally accepted that when true change occurs in the setting of a clinical trial, disease-specific measures are more responsive to this change as compared to generic measures of HRQL [ 22].
Pre-trial disease progression was radiologically confirmed and independently reviewed.
Of the instruments other than QoL, in 51 (48 %) trials disease-specific instruments for outcome measurement were used and in 38 (36 %) trials non-disease-specific instruments were used.
In such trials, disease specific quality of life questionnaires could be a core outcome domain [ 16] in addition to pain, shoulder specific function, and work ability.
Specifically, they have recommended that the following constitute a core set of domains for SLE clinical trials: disease activity, HR-QOL, adverse events, and cumulative organ damage [ 25, 26].
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com